Cablivi

Cablivi (caplacizumab) is a medication used to manage certain blood clotting disorders. This intravenous or subcutaneous treatment is designed to help prevent clotting complications in specific conditions.

Cablivi is primarily used to manage acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. It works by targeting von Willebrand factor, a protein involved in blood clotting. Patients may wonder, 'What is Cablivi used for?'—it is specifically indicated for aTTP to reduce the risk of blood clots and related complications.

Common effects of Cablivi may include mild bleeding or bruising at the injection site. Some users might experience headaches or nausea. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Cablivi should be used with caution in patients with a history of bleeding disorders. It is important to follow the prescribed administration route, whether intravenous or subcutaneous, to ensure proper delivery. Always consult a healthcare professional before starting or stopping any medication.

Cablivi may interact with other medications that affect blood clotting, such as anticoagulants. It is also important to avoid alcohol, as it can increase the risk of bleeding. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.